33.96
0.77%
0.26
アフターアワーズ:
34.11
0.15
+0.44%
前日終値:
$33.70
開ける:
$33.83
24時間の取引高:
4.15M
Relative Volume:
0.75
時価総額:
$69.29B
収益:
$39.71B
当期純損益:
$3.17B
株価収益率:
9.8655
EPS:
3.4423
ネットキャッシュフロー:
$6.05B
1週間 パフォーマンス:
+1.83%
1か月 パフォーマンス:
-10.63%
6か月 パフォーマンス:
-25.82%
1年 パフォーマンス:
-3.52%
Gsk Plc Adr Stock (GSK) Company Profile
GSK を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
GSK | 33.96 | 69.29B | 39.71B | 3.17B | 6.05B | 3.4423 |
LLY | 748.01 | 710.91B | 40.86B | 8.37B | -2.28B | 5.4193 |
NVO | 105.06 | 466.80B | 39.36B | 13.79B | 9.83B | 2.4077 |
JNJ | 155.17 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
ABBV | 176.95 | 312.70B | 55.53B | 5.12B | 15.62B | 3.65 |
MRK | 99.18 | 250.89B | 63.17B | 12.15B | 14.84B | 1.80 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-07-08 | ダウングレード | UBS | Buy → Neutral |
2024-05-30 | 開始されました | Goldman | Neutral |
2024-03-04 | アップグレード | Guggenheim | Neutral → Buy |
2024-02-13 | アップグレード | Citigroup | Neutral → Buy |
2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
2024-01-16 | 再開されました | UBS | Buy |
2024-01-03 | アップグレード | Jefferies | Hold → Buy |
2023-07-14 | 開始されました | HSBC Securities | Reduce |
2023-03-17 | アップグレード | Deutsche Bank | Hold → Buy |
2023-02-27 | 再開されました | Goldman | Buy |
2023-01-03 | ダウングレード | JP Morgan | Neutral → Underweight |
2022-12-05 | ダウングレード | BofA Securities | Neutral → Underperform |
2022-11-11 | ダウングレード | UBS | Neutral → Sell |
2022-09-15 | アップグレード | Credit Suisse | Underperform → Neutral |
2022-09-08 | ダウングレード | Jefferies | Buy → Hold |
2022-08-05 | 再開されました | Morgan Stanley | Equal-Weight |
2022-07-21 | 再開されました | Citigroup | Neutral |
2022-02-11 | ダウングレード | DZ Bank | Buy → Hold |
2021-11-05 | アップグレード | Barclays | Underweight → Equal Weight |
2021-06-24 | アップグレード | Deutsche Bank | Sell → Hold |
2021-03-23 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2021-02-04 | ダウングレード | Deutsche Bank | Hold → Sell |
2021-01-20 | ダウングレード | Credit Suisse | Neutral → Underperform |
2021-01-15 | 開始されました | Deutsche Bank | Hold |
2020-11-02 | アップグレード | Liberum | Hold → Buy |
2020-09-29 | 開始されました | Berenberg | Buy |
2020-02-12 | ダウングレード | Shore Capital | Hold → Sell |
2020-01-16 | ダウングレード | Barclays | Equal Weight → Underweight |
2019-12-02 | 開始されました | SVB Leerink | Outperform |
2019-11-21 | アップグレード | UBS | Neutral → Buy |
2019-10-11 | アップグレード | Cantor Fitzgerald | Hold → Buy |
2019-09-03 | 再開されました | Citigroup | Neutral |
2019-09-03 | アップグレード | Societe Generale | Sell → Buy |
2019-08-13 | 再開されました | JP Morgan | Neutral |
2019-06-17 | 再開されました | Morgan Stanley | Underweight |
2019-03-08 | ダウングレード | Shore Capital | Buy → Hold |
2019-02-22 | ダウングレード | UBS | Buy → Neutral |
2019-01-14 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
2018-12-11 | 再開されました | Jefferies | Buy |
2018-10-09 | 開始されました | Guggenheim | Neutral |
2018-08-30 | ダウングレード | Liberum | Buy → Hold |
2018-04-04 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
2018-03-22 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
2018-02-09 | アップグレード | Kepler | Reduce → Hold |
すべてを表示
Gsk Plc Adr (GSK) 最新ニュース
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients - Benzinga
5 Stocks to Buy While They’re Still Cheap After Earnings - Morningstar
Diabetes Care Nutrition Market Report 2024 with Forecasts to 2029 - GlobeNewswire Inc.
The 10 Best Companies to Invest in Now - Morningstar
Weekly Upgrades and Downgrades - InvestorPlace
The Best Defensive Stocks to Buy - Morningstar
GSK Plc ADR (NYSE: GSK) Has Outstanding Potential - Stocks Register
GSK (GSK) Q3 Earnings Surpass Estimates - Yahoo Finance
What Do Analysts Think About ICICI Bank Ltd. ADR’s (NYSE:IBN) Future? - Stocks Register
GSK Plc ADR (GSK): An Important Analyst Insights - Stocks Register
5 Stocks to Buy if You’re Concerned About US Market Valuations - Morningstar
21 Best Healthcare Companies to Invest In - Morningstar
Current share price is - GSK
D-Wave Quantum Inc (QBTS) rating initates by B. Riley Securities - Knox Daily
GSK's Studies On Depemokimab For Nasal Polyps Meet Primary Goals - Barchart
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
GSK Plc ADR [GSK] is 5.59% higher this YTD. Is it still time to buy? - The DBT News
What You Didn’t Know About General Motors Company (NYSE: GM) This Week - Stocks Register
GSK’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Before You Invest, Make Sure You Check This ADT Inc (NYSE: ADT) Analysis - Stocks Register
What Are You Thinking About Investing In Medical Properties Trust Inc (NYSE: MPW) Stock? - Stocks Register
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday - sharewise
Introducing Our Rant Against GSK Plc ADR - US Post News
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy - Zacks Investment Research
Balance Sheet Insights: GSK Plc ADR (GSK)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Pilgrim’s Pride Corp. (PPC) receives an Equal-weight rating from Stephens - Knox Daily
Berenberg upgrades Carnival plc ADR (CUK) stock to a Hold - Knox Daily
JP Morgan analysts downgrades an Underweight rating for Organon & Co. (OGN) - Knox Daily
GSK Plc ADR (GSK) gets rating Downgrade from UBS - Knox Daily
GSK Plc ADR (GSK) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine
Precidian to List First ADRhedged Securities in the U.S. on Cboe, Providing Exposure to Individual International Companies with an Embedded Currency Hedge - PR Newswire
Tenet Healthcare Corp. [THC] stock for 1,879,734 USD was sold by Ramsey R. Scott - Knox Daily
Ratio Analysis: Unpacking GSK Plc ADR (GSK)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
GSK Plc ADR [GSK] Insider Activity: An Update for Investors - Knox Daily
GSK Plc ADR (GSK) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Cantor Fitzgerald’s latest rating for AMGN stock - Knox Daily
Nutanix Inc [NTNX] Chief Financial Officer makes an insider sale of 24,316 shares worth 1,430,939. - Knox Daily
GSK’s Stock Market Adventure: 9.44% YTD Growth Amidst Volatility - The InvestChronicle
GSK Shares Experience Decline in Value - Knox Daily
The Best Healthcare Stocks to Buy - Morningstar
Gsk Plc Adr (GSK) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):